Get the Stockscreener App
1.58
7.60%
-0.13
Pre-market:
1.69
0.11
+6.96%
Sellas Life Sciences Group Inc stock is traded at $1.58, with a volume of 3.47M.
It is down -7.60% in the last 24 hours and down -9.20% over the past month.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
See More
Previous Close:
$1.71
Open:
$1.83
24h Volume:
3.47M
Relative Volume:
1.98
Market Cap:
$157.65M
Revenue:
-
Net Income/Loss:
$-37.34M
P/E Ratio:
-1.1618
EPS:
-1.36
Net Cash Flow:
$-36.91M
1W Performance:
-16.40%
1M Performance:
-9.20%
6M Performance:
+36.21%
1Y Performance:
+12.06%
1-Day Range:
$1.57
$1.83
1-Week Range:
$1.57
$2.12
52-Week Range:
$0.772
$2.12
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Name
Sellas Life Sciences Group Inc
Sector
Industry
Phone
(646) 200-5278
Address
7 TIMES SQUARE, NEW YORK, NY
Compare SLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
1.58 | 192.57M | 0 | -37.34M | -36.91M | -1.36 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-18 | Initiated | Oppenheimer | Outperform |
| Apr-02-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Upgrade | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Stock (SLS) Latest News
SELLAS reports potential colorectal cancer therapy progress - Investing.com India
SELLAS reports potential colorectal cancer therapy progress By Investing.com - Investing.com Nigeria
Sellas Life Sciences Group, Inc. Presents Preclinical Efficacy of Sls009 in Asxl1 Mutated Colorectal Cancer At 2025 Asco Annual Meeting - marketscreener.com
SELLAS Life Sciences (SLS) Highlights Promising Results for SLS009 in Cancer Study | SLS Stock News - GuruFocus
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting - GlobeNewswire
Breakthrough at ASCO: SELLAS Drug Shows Powerful Response in Targeted Colorectal Cancer Treatment - Stock Titan
Insider Buying: Katherine Kalin Acquires 20,000 Shares of SELLAS Life Sciences Group Inc (SLS) - GuruFocus
US futures and global markets tumble after Trump threatens European Union with 50% tariffs and Apple with 25% tariff - The Globe and Mail
Sellas Life Sciences Reports Improved Financial Position - TipRanks
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase - The Manila Times
SELLAS Life Sciences CEO to Reveal Latest Cancer Drug Development Strategy at Major Healthcare Conference - Stock Titan
Sellas doses first paediatric subject with AML in Phase II trial of SLS009 - Yahoo Finance
SELLAS advances pediatric AML treatment with Phase 2 trial By Investing.com - Investing.com South Africa
Sellas Life Sciences Doses 1st Pediatric Patient in Acute Myeloid Leukemia Study - marketscreener.com
SELLAS Life Sciences (SLS) Advances Phase 2 Trial for Pediatric AML | SLS Stock News - GuruFocus
SELLAS advances pediatric AML treatment with Phase 2 trial - Investing.com
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML - GlobeNewswire
Breakthrough: First Child with Resistant Leukemia Receives New Treatment in Major Clinical Trial - Stock Titan
SELLAS Life Sciences (SLS) Reports Improved Q1 Earnings Amid Fin - GuruFocus
SLS009 Shows Promising Results in Latest AML Trials | SLS Stock News - GuruFocus
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
SELLAS Life Sciences Group Reports Positive Overall Survival Data for SLS009 in r/r AML and Updates on Financial Position and Pipeline Developments - Nasdaq
SELLAS Life Sciences (SLS) Reports Improved Q1 Earnings Amid Financial Boost - GuruFocus
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.
SELLAS Life Sciences Group (SLS) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Upward Trajectory: SELLAS Life Sciences Group Inc (SLS) Posts a Gaine, Closing at 1.72 - DWinneX
Financial Metrics Exploration: Understanding SELLAS Life Sciences Group Inc (SLS) Through Ratios - DWinneX
Geode Capital Management LLC Purchases 128,355 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World
Wall Street analysts’ outlook for SELLAS Life Sciences Group Inc (SLS) - Sete News
SELLAS Life Sciences Group Inc’s latest rating changes from various analysts - knoxdaily.com
SELLAS Life Sciences Group Inc (SLS) Stock: The Story of a 52-Week Stock Range - investchronicle.com
Understanding the Risks of Investing in La Rosa Holdings Corp (LRHC) - knoxdaily.com
SELLAS reports promising AML treatment in preclinical study - Investing.com
SELLAS Life Sciences (SLS) Reports Promising Preclinical Results for SLS009 in Leukemia | SLS Stock News - GuruFocus
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference - The Manila Times
Breakthrough: New Cancer Drug SLS009 Extends AML Patient Survival by 252% in Clinical Trial Data - Stock Titan
SELLAS Life Sciences Group Inc: Navigating Market Fluctuations with a 127.18M Market Cap - investchronicle.com
The time has not yet come to remove your chips from the table: SELLAS Life Sciences Group Inc (SLS) - Sete News
BILI Shares Experience Surge in Value - knoxdaily.com
SLSSellas Life Sciences Group Inc Latest Stock News & Market Updates - Stock Titan
Ratio Review: Analyzing fuboTV Inc (FUBO)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Financial Fitness Check: Examining Royalty Pharma plc (RPRX)’s Key Ratios - DWinneX
SELLAS Life Sciences Group (NASDAQ:SLS) Trading 1.6% Higher – Time to Buy? - Defense World
Amazon's Earnings Could Fuel a Rapid Breakout - The Globe and Mail
SELLAS Life Sciences Group, Inc. to Present Preclinical Efficacy Data for SLS009 in ASXL1 Mutated Colorectal Cancer at ASCO 2025 Annual Meeting - Nasdaq
SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewswire
Clinical Trial Breakthrough: SELLAS Unveils Novel Cancer Drug Results for Hard-to-Treat ASXL1 Mutations - Stock Titan
How did SELLAS Life Sciences Group Inc (SLS) fare last session? - uspostnews.com
Analysts review SELLAS Life Sciences Group Inc’s rating - knoxdaily.com
Loop Capital analysts downgrades a Sell rating for Canadian National Railway Co (CNI) - knoxdaily.com
Analysts Are Recommending SELLAS Life Sciences Group Inc (SLS) As A Buy Candidate - Marketing Sentinel
Sellas Life Sciences Group Inc Stock (SLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):